ArticleJournal of family medicine and primary care2025
Hemoglobin A1C in the first trimester of pregnancy as a predictor of gestational diabetes mellitus: A retrospective study in Saudi Arabia.
Article in Journal of family medicine and primary care, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Aim: This study evaluates the association between first-trimester hemoglobin A1c (HbA1c) levels and glucose tolerance test (GTT) results to assess the utility of HbA1c as a predictive biomarker for gestational diabetes mellitus (GDM). Methods: A retrospective, descriptive study was conducted on 634 pregnant women between January and December 2022 at Prince Sultan Military Medical City, Riyadh, Saudi Arabia. After excluding cases with HbA1c ≥6.5% (48 mmol/mol), 552 participants were included in the final analysis. Data on demographic characteristics, HbA1c levels, biochemical parameters, and GTT results were collected and analyzed. Results: Out of 552 participants, 183 (33%) were diagnosed with GDM. Among those with elevated HbA1c levels (≥5.6), 59 (54%) had GDM. Additionally, 99 (17.9%) women had a single positive oral glucose tolerance test (OGTT), while 50 (9.1%) had two positives, and 34 (6.2%) had three positives. A significant difference in fasting glucose levels was observed between pregnant women with GDM and normal HbA1c (<5.6%) (4.78 ± 0.76) and those with elevated HbA1c (≥5.6%) (5.39 ± 1.47) ( Conclusion: Measurement of HbA1c during the first trimester may be a useful approach for identifying pregnant women at an increased risk of GDM. Incorporating HbA1c testing into standard prenatal care could enable earlier risk assessment and prompt interventions, helping to reduce unfavorable outcomes for both mother and fetus. Additional research is needed to confirm these results and determine the most appropriate HbA1c cutoff values for clinical practice.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.